aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
May 02, 2024 16:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma announces first quarter 2024 results and provides corporate update
aTyr Pharma to Participate in April Investor Conferences
April 01, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
March 14, 2024 16:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
February 28, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
February 21, 2024 08:00 ET
|
aTyr Pharma, Inc.
Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
January 29, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
January 18, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
November 13, 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its...
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
November 09, 2023 16:00 ET
|
aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated...
aTyr Pharma to Present at November Investor Conferences
November 01, 2023 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma announces that it will present at two investor conferences in November 2023.